Akebia Therapeutics (AKBA) Interest & Investment Income (2015 - 2026)
Akebia Therapeutics (AKBA) reported Interest & Investment Income of -$4.7 million for Q1 2026, up 39.63% year-over-year from -$3.4 million in Q1 2025, and up 2.82% quarter-over-quarter from -$4.8 million in Q4 2025.
Akebia Therapeutics (AKBA) Interest & Investment Income (2015 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has 12 years of Interest & Investment Income data on file, last reported at -$4.7 million in Q1 2026.
- Interest & Investment Income for Q1 2026 came in at -$4.7 million, up 39.63% year-over-year; the trailing twelve-month figure through Mar 2026 was -$21.1 million (up 10.05% YoY), and the FY2025 annual result was -$24.2 million, down 32.96% from the prior year.
- Interest & Investment Income advanced to -$4.7 million in Q1 2026 per AKBA's latest filing, from -$4.8 million in the prior quarter.
- Over five years, Interest & Investment Income peaked at -$1.4 million in Q3 2023 and troughed at -$7.8 million in Q1 2025.
- A 5-year average of -$4.0 million and a median of -$4.7 million in 2026 frame the typical range for Interest & Investment Income.
- The sharpest annual moves came in 2023 and 2024: Interest & Investment Income jumped 69.16% in 2023, then sank 384.98% in 2024.
- A 5-year view of Interest & Investment Income shows it stood at -$1.6 million in 2022, then grew by 13.33% to -$1.4 million in 2023, then sank by 384.98% to -$6.9 million in 2024, then gained by 29.81% to -$4.8 million in 2025, then climbed by 2.82% to -$4.7 million in 2026.
- Business Quant data shows AKBA's Interest & Investment Income at -$4.7 million in Q1 2026, -$4.8 million in Q4 2025, and -$4.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn | - |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn | - |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn | 41.80 Mn |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn | 3.45 Mn |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn | 28.10 Mn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn | 8.54 Mn |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn | 4.97 Mn |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn | - |
| 10 | Akebia Therapeutics | 235.00 Mn | 72.40 Mn | 41.25 Mn | -4.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.69 Mn |
| Dec 31, 2025 | -4.83 Mn |
| Sep 30, 2025 | -4.75 Mn |
| Jun 30, 2025 | -6.83 Mn |
| Mar 31, 2025 | -7.77 Mn |
| Dec 31, 2024 | -6.88 Mn |
| Sep 30, 2024 | -6.66 Mn |
| Jun 30, 2024 | -2.15 Mn |
| Mar 31, 2024 | -2.50 Mn |
| Dec 31, 2023 | -1.42 Mn |
| Sep 30, 2023 | -1.41 Mn |
| Jun 30, 2023 | -1.64 Mn |
| Mar 31, 2023 | -1.56 Mn |
| Dec 31, 2022 | -1.64 Mn |
| Sep 30, 2022 | -3.95 Mn |
| Jun 30, 2022 | -5.04 Mn |
| Mar 31, 2022 | -5.06 Mn |
| Dec 31, 2021 | -5.08 Mn |
| Sep 30, 2021 | -5.09 Mn |
| Jun 30, 2021 | -4.96 Mn |